ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how the rules link it today.

Why Lymphoma, Large B-Cell, Diffuse is on this study

  • ClinicalTrials.gov files the study under Lymphoma, Large B-Cell, Diffuse.
  • It is the study's main condition, by the main-condition rule: the study is compared with others under Lymphoma, Large B-Cell, Diffuse.
  • Rule based: the finest condition the study states.
13 links0 made here, not in the record14 judgments1 judge (the rules as one: Rule based)1 record change seen
Rule basedRecord updated on ClinicalTrials.gov
Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT04529772A Combination ofAcalabrutinib With R-CHOPin Subjects With PreviouslyUntreated Non-GCB DLBCL(ACE-LY-312)Acerta Pharma BVPhase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 13 · ClinicalTrials.gov record · Version of 2026-10-13Version of 2026-10-13CONDITIONSLymphoma, Large B-Cell, Dif…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionLymphomaThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseLymphoma, B-CellThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseLymphoproliferative Disorde…The registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedLymphatic DiseasesThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedLymphoma, Non-HodgkinThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSAcalabrutinibIntervention entry›As of now · Rule based · TestedTestedPrednisoneIntervention entry›As of now · Rule based · BackgroundBackgroundRituximabIntervention entry›As of now · Rule based · BackgroundBackgroundCyclophosphamideIntervention entry›As of now · Rule based · BackgroundBackgroundVincristineIntervention entry›As of now · Rule based · BackgroundBackgroundDoxorubicinIntervention entry›As of now · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Oct 13 · changes seen, not judgments
Nov 14Lymphoma, Large B-Cell, DiffuseRule based · condition-kind ruleFinest filed termCurrent
Nov 14LymphomaRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Lymphoma, B-CellRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Lymphoproliferative DisordersRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Lymphatic DiseasesRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Lymphoma, Non-HodgkinRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
As of nowLymphoma, Large B-Cell, DiffuseRule based · main-condition ruleMain conditionCurrent
As of nowAcalabrutinibRule based · role ruleTestedCurrent
As of nowPrednisoneRule based · role ruleBackgroundCurrent
As of nowRituximabRule based · role ruleBackgroundCurrent
As of nowCyclophosphamideRule based · role ruleBackgroundCurrent
As of nowVincristineRule based · role ruleBackgroundCurrent
As of nowDoxorubicinRule based · role ruleBackgroundCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.